Indeed, a real-world study shows that people treated with PCSK9 inhibitors are associated with mild hyperglycemia,31 but there is no firm proof to support the association between PCSK9 inhibitors usage and the risk of NOD.32 However, based on our findings, the pathological effect of PCSK9 on pancreatic β-cells should be considered in the pathogenesis of statin-associated diabetes. This evidence concerns the gene PCSK9 and diabetes mellitus.